Anebulo Pharmaceuticals I... (ANEB)
1.01
0.04 (4.12%)
At close: Apr 23, 2025, 3:59 PM
0.89
-11.76%
Pre-market: Apr 24, 2025, 04:00 AM EDT
Company Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction.
Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
The company was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals Inc.

Country | United States |
IPO Date | May 7, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 2 |
CEO | Richard Anthony Cunningham |
Contact Details
Address: 1415 Ranch Road 620 South Lakeway, Texas United States | |
Website | https://www.anebulo.com |
Stock Details
Ticker Symbol | ANEB |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001815974 |
CUSIP Number | 034569103 |
ISIN Number | US0345691036 |
Employer ID | 85-1170950 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Richard Anthony Cunningham | Chief Executive Officer & Director |
Daniel V. George | Acting Chief Financial Officer & Secretary |
Dr. Joseph F. Lawler M.D., Ph.D. | Founder & Chairman |
Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 15, 2025 | 8-K | Current Report |
Apr 14, 2025 | 8-K | Current Report |
Apr 07, 2025 | 4 | Filing |
Apr 07, 2025 | 4 | Filing |
Apr 07, 2025 | 4 | Filing |
Apr 07, 2025 | 4 | Filing |
Apr 07, 2025 | 4 | Filing |
Apr 07, 2025 | 4 | Filing |
Apr 07, 2025 | 4 | Filing |
Apr 07, 2025 | 4 | Filing |